IMT Header

Cambridge Healthtech Institute’s 10th Annual
Novel Vaccines
Part One: Adjuvants
August 24-25


Many recently developed vaccines are comprised of recombinant molecules or subunits of pathogenic organisms, requiring formulation with adjuvants to increase and direct the immune response. The benefit of adjuvants is clear: they may reduce the amount of antigen and number of vaccinations needed, accelerate the immune response, increase cross-protection, and improve efficacy in populations that are poor responders. As we continue to confront emerging and re-emerging disease threats and progress toward developing new vaccines to improve global health, there is also an urgent need for the development of novel adjuvants. CHI’s Tenth Annual Novel Vaccines: Adjuvants meeting will cover the latest advances in a range of adjuvants, from archaeosomes to TLRs, present case studies of successful formulations against challenging diseases, and address issues related to regulatory approval and understanding mode of action.

NEXT-GENERATION ADJUVANTS 

The Next Generation of Vaccine Adjuvants

Derek O’Hagan, Ph.D., Global Head, Vaccine Chemistry & Formulations, Novartis Vaccines & Diagnostics

Novel Archael Lipid-Based Semi-Synthetic Adjuvant for Induction of Cell-Mediated Immunity

Lakshmi Krishnan, Ph.D., Team Leader, Human Health Therapeutics, National Research Council, Canada

The Use of a Novel Nanoemulsion Adjuvant for both Prophylactic and Therapeutic Intranasal Vaccination

Ali Fattom, Ph.D., Senior Vice President, Vaccine R&D, NanoBio

FDA Perspective: Regulatory Considerations in the Safety Assessment of Vaccine Adjuvants and Adjuvanted Vaccines

Carmen M. Collazo-Custodio, Ph.D., Microbiology & Primary Reviewer, Vaccines & Related Product Applications, CBER, FDA


ADVANCES IN DNA, TLR AND COMBINATION ADJUVANTS 

Talk Title to be Announced

Shan Lu, M.D., Ph.D., Professor, Medicine, University of Massachusetts Medical School

Engineered Forms of the TLR5 Agonist, Flagellin, Support Highly Immunogenic Subunit Vaccines

Lynda Tussey, Ph.D., Vice President, R&D, VaxInnate

Nanoliposome Delivery Systems to Trigger Multiple Pattern Recognition Receptors

Susan Lin, Process Development Associate, Infectious Disease Research Institute


UNDERSTANDING MODE OF ACTION and De-Risking Design 

Mode of Action of Adjuvant System AS01

Arnaud Didierlaurent, Ph.D., Senior Scientist, Vaccine Research Unit – Vaccine Mode of Action, GlaxoSmithKline Vaccines

De-Risking Formulation Design

Roger H. Brookes, Ph.D., Bioprocess R&D, Sanofi Pasteur

Effect of Formulation and Particle Size on Stability and Immunogenicity of Oil-in-Water Emulsion Adjuvants

Vidyashankara Iyer, Ph.D., Scientist, Formulation Sciences, MedImmune


ADDRESSING UNMET VACCINE NEEDS 

A Replication Defective Human Cytomegalovirus (CMV) Vaccine

Tong-Ming Fu, Ph.D., Senior Investigator, Merck

Preventing RSV Disease in Young Infants

Deborah Higgins, Ph.D., Scientific Director, RSV Vaccine Project, PATH


For more details on the conference, please contact:
Virginia Maxwell
Associate Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5436
E: vmaxwell@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com